利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

26 条记录 (耗时 0.046 秒)

    Inducible phosphofructokinase and the Warburg effect
    9.
    发明授权
    Inducible phosphofructokinase and the Warburg effect 失效
    诱导型磷酸果糖激酶和Warburg效应

    公开(公告)号：US06596851B1

    公开(公告)日：2003-07-22

    申请号：US09670216

    申请日：2000-09-25

    申请人： Richard J. Bucala ,  Jason A. Chesney ,  Robert A. Mitchell

    发明人： Richard J. Bucala ,  Jason A. Chesney ,  Robert A. Mitchell

    IPC分类号： C07K1600

    CPC分类号： C12N9/1205 ,  A61K38/00 ,  C12Y207/01105

    摘要： There is disclosed a cancer malignancy diagnostic assay comprising obtaining a sample of a body fluid or tissue, performing a sequence identity assay to look for the presence of iPFK-2 specific sequences; an anticancer pharmaceutical composition comprising a specific antisense oligonucleotide to the inventive isolated iPFK-2 sequence and a pharmaceutically acceptable oligonucleotide carrier; and a method for finding therapeutically active anti-cancer compounds comprising screening compounds for activity to inhibit iPFK-2, preferably kinase activity.

    摘要翻译： 公开了一种癌症恶性肿瘤诊断测定法，其包括获得体液或组织的样品，进行序列同一性测定以寻找iPFK-2特异性序列的存在; 包含本发明的分离的iPFK-2序列的特异性反义寡核苷酸和药学上可接受的寡核苷酸载体的抗癌药物组合物; 以及用于发现治疗活性抗癌化合物的方法，包括筛选用于抑制iPFK-2的活性的化合物，优选激酶活性。

    Compounds having MIF antagonist activity
    10.
    发明授权
    Compounds having MIF antagonist activity 失效
    具有MIF拮抗剂活性的化合物

    公开(公告)号：US06492428B1

    公开(公告)日：2002-12-10

    申请号：US09625829

    申请日：2000-07-26

    申请人： Yousef Al-Abed ,  Richard J. Bucala ,  Robert A. Mitchell ,  Peter Senter

    发明人： Yousef Al-Abed ,  Richard J. Bucala ,  Robert A. Mitchell ,  Peter Senter

    IPC分类号： A61K3117

    CPC分类号： A61K31/122 ,  A61K31/167

    摘要： There are disclosed methods of use and pharmaceutical compositions for two related genera of low molecular weight compounds comprising optionally substituted iminoquinone or orthoquinone ring systems. The compounds have MIF (macrophage migration inhibitory factor) antagonist activity and find utility as such. For example, the compounds are useful for treating a variety of diseases involving inflammatory activity or pro-inflammatory cytokine responses, such as autoimmune diseases (including rheumatiod arthritis, insulin-dependent diabetes, multiple sclerosis, graft versus host disease, lupus syndromes), asthma, arthritis, EAE, ARDS, psoriasis, interleukin-2 toxicity, proliferative vascular disease, and various forms of sepsis and septic shock, and other conditions characterized by underlying MIF responses including, for instance, tumor growth and neovascularization (angiogenesis).

    摘要翻译： 公开了使用的方法和用于两种相关属的低分子量化合物的药物组合物，其包含任选取代的亚氨基醌或正醌环系。 这些化合物具有MIF（巨噬细胞迁移抑制因子）拮抗剂活性，并发现其效用。 例如，该化合物可用于治疗涉及炎症活性或促炎细胞因子应答的各种疾病，例如自身免疫疾病（包括风湿性关节炎，胰岛素依赖性糖尿病，多发性硬化，移植物抗宿主病，狼疮综合征），哮喘 ，关节炎，EAE，ARDS，牛皮癣，白细胞介素-2毒性，增殖性血管疾病和各种形式的败血症和败血性休克，以及其他由潜在的MIF反应（包括例如肿瘤生长和新生血管形成）（血管发生）表征的病症。